

Table 2.4. Case-control studies of combined estrogen-progestogen menopausal therapy and endometrial cancer

Reference, study location, and period	Characteristics of cases	Characteristics of controls	Exposure assessment	Exposure categories	Relative risk	95% CI	Comments
Weiss, JM, <i>et al.</i> (2006), United States, western Washington state, 3 counties	1304 women aged 45–74 years old with endometrial cancer diagnosed 1985-1991, 1994-1995, and 1997-1999.	1779 women randomly identified by random digit dialing, aged 45–74, with intact uteri and no prior endometrial cancer history	Structured, in-person interview, less often telephone interview	Yes/No Unopposed estrogen Sequential estrogen plus progestogen E opposed by P for <10 days/month for ≥4 years E opposed by P for 10-24 days/month for ≥4 years Continuous combined E + P (progestogen for >24 days/month) for ≥4 years	low: 18.6; mod.: 9.8; high: 7.1 low: 6.2; mod.: 3.1; high: 1.6 low: 2.9 mod.: 1.4 high: 1.0 low: 0.7 mod.: 1.0 high: 1.6	12.2–28.6 3.2–12.0 1.6–6.1 0.4–7.2 1.6–5.0 0.8–2.5 0.3–3.4 0.3–1.7 0.6–1.7 0.7–3.8	Three population-based case-control studies, identified by Cancer Surveillance System—affiliated with SEER Program of the National Cancer Institute. Tumour aggressiveness: low, moderate [mod.], and high

Table 2.4. Case-control studies of combined estrogen-progestogen menopausal therapy and endometrial cancer

Reference, study location, and period	Characteristics of cases	Characteristics of controls	Exposure assessment	Exposure categories	Relative risk	95% CI	Comments
Strom, BL, <i>et al.</i> , (2006), Philadelphia, PA, United States	511 postmenopausal women, aged 50–79 years, newly diagnosed w. endometrial cancer between 1999–2002	1412 postmenopausal women age-group and race-matched, with intact uteri, identified by random digit dialling	Active surveillance of regional hospitals detected cases; random digit dialling detected controls; history of hormone use by telephone interviews with memory aids mailed in advance	ERT [unopposed estrogen]	3.4	1.4–8.3	Population-based case-control study. CHRT = combination estrogen and progestin replacement therapy (pills or patches); continuous combined HRT = estrogen combined with 25-31 days/month of progestin use. Standard sequential CHRT = estrogen combined with 5–14 days/month of progestin use. Combined E+P hormone therapy is not associated with increased risk for endometrial cancer.
				CHRT [combination estrogen and progestion therapy]	0.8	0.6–1.1	
				Never	1		
				Ever			
				Ever use /any duration CHRT	0.8	0.58–1.11	
				≥3 years	0.86	0.59–1.27	
Ever use only standard sequential CHRT	0.89	0.39–2.05					
Ever use only continuous CHRT	0.77	0.33–1.81					